Dalbavancin in the Treatment of Bacteremia and Endocarditis in People with Barriers to Standard Care
Introduction: Dalbavancin is an antibiotic administered by intravenous infusion weekly or bi-weekly and is currently FDA-approved only for treatment of skin and soft-tissue infections. It has shown promise, but is not considered the standard of care, for bacteremia and infective endocarditis (IE), w...
Saved in:
Main Authors: | Leama Ajaka (Author), Emily Heil (Author), Sarah Schmalzle (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2020-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Dalbavancin versus standard of care for the treatment of osteomyelitis in adults: A retrospective matched cohort study
by: Thamer A. Almangour, et al.
Published: (2020) -
DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci
by: Carmen Hidalgo-Tenorio, et al.
Published: (2019) -
Dalbavancin in the treatment of skin and soft tissues infection
by: Ana Candela Fajardo, et al.
Published: (2017) -
Clinical outcomes following dalbavancin administration in patients with barriers to outpatient parenteral antimicrobial therapy
by: Jessica J. Tuan, et al.
Published: (2022) -
Dalbavancin for the Treatment of Prosthetic Joint Infections: A Narrative Review
by: Luis Buzón-Martín, et al.
Published: (2021)